GeoVax Labs, Inc. (Nasdaq: GOVX) is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 115 granted or pending patent applications spread over 24 patent families.
GeoVax’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The company’s lead infectious disease program is CM04S1, a next-generation Covid-19 vaccine targeting high-risk immunocompromised patient populations. Currently in two Phase 2 clinical trials, CM04S1 is being evaluated as a single-dose, Covid-19 vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized Covid-19 vaccines are insufficient. In addition, CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable Covid-19 booster among healthy patients who previously received the mRNA vaccines.
Additional research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria.
Recent Press Releases
- GeoVax to Participate at the World Vaccine Congress with Multiple Presentations
- GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update
- GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress
- GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update
News of Interest
GeoVax 2022 Earnings - Webcast
Contact Us
GeoVax Labs, Inc.
1900 Lake Park Drive, Suite 380
Atlanta, GA 30080
Tel: (678) 384-7220
Email: investor@geovax.com